Acknowledgement
This work was supported by a grant (NRF-2019R1A2C 1086151 to J.-A.K.) from the National Research Foundation, Ministry of Science and ICT and Future Planning and by the Korea Research Institute of Bioscience and Biotechnology (KRIBB) Research Initiative Program (171134054 to J.-A.K. and KGM99922111 to J.-H.K. [Jeong-Hoon Kim] and J.-A. K.).
References
- Abou-Alfa, G.K., Meyer, T., Cheng, A.L., El-Khoueiry, A.B., Rimassa, L., Ryoo, B.Y., Cicin, I., Merle, P., Chen, Y., Park, J.W., et al. (2018). Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N. Engl. J. Med. 379, 54-63. https://doi.org/10.1056/NEJMoa1717002
- Albert, M. and Helin, K. (2010). Histone methyltransferases in cancer. Semin. Cell Dev. Biol. 21, 209-220. https://doi.org/10.1016/j.semcdb.2009.10.007
- Brown, R., Curry, E., Magnani, L., Wilhelm-Benartzi, C.S., and Borley, J. (2014). Poised epigenetic states and acquired drug resistance in cancer. Nat. Rev. Cancer 14, 747-753. https://doi.org/10.1038/nrc3819
- Bruix, J., Qin, S., Merle, P., Granito, A., Huang, Y.H., Bodoky, G., Pracht, M., Yokosuka, O., Rosmorduc, O., Breder, V., et al. (2017). Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 389, 56-66. https://doi.org/10.1016/S0140-6736(16)32453-9
- Cao, X., Ding, Q., Lu, J., Tao, W., Huang, B., Zhao, Y., Niu, J., Liu, Y.J., and Zhong, J. (2015). MDA5 plays a critical role in interferon response during hepatitis C virus infection. J. Hepatol. 62, 771-778. https://doi.org/10.1016/j.jhep.2014.11.007
- Chen, Z., Xie, H., Hu, M., Huang, T., Hu, Y., Sang, N., and Zhao, Y. (2020). Recent progress in treatment of hepatocellular carcinoma. Am. J. Cancer Res. 10, 2993-3036.
- Cheng, Y., He, C., Wang, M., Ma, X., Mo, F., Yang, S., Han, J., and Wei, X. (2019). Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials. Signal Transduct. Target. Ther. 4, 62.
- de Lope, C.R., Tremosini, S., Forner, A., Reig, M., and Bruix, J. (2012). Management of HCC. J. Hepatol. 56 Suppl 1, S75-S87.
- Deliu, E., Arecco, N., Morandell, J., Dotter, C.P., Contreras, X., Girardot, C., Kasper, E.L., Kozlova, A., Kishi, K., Chiaradia, I., et al. (2018). Haploinsufficiency of the intellectual disability gene SETD5 disturbs developmental gene expression and cognition. Nat. Neurosci. 21, 1717-1727. https://doi.org/10.1038/s41593-018-0266-2
- Dillon, S.C., Zhang, X., Trievel, R.C., and Cheng, X. (2005). The SET-domain protein superfamily: protein lysine methyltransferases. Genome Biol. 6, 227.
- Dobin, A., Davis, C.A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., and Gingeras, T.R. (2013). STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15-21. https://doi.org/10.1093/bioinformatics/bts635
- Feng, G.S., Hanley, K.L., Liang, Y., and Lin, X. (2021). Improving the efficacy of liver cancer immunotherapy: the power of combined preclinical and clinical studies. Hepatology 73 Suppl 1, 104-114.
- Fernandes, I.R., Cruz, A.C.P., Ferrasa, A., Phan, D., Herai, R.H., and Muotri, A.R. (2018). Genetic variations on SETD5 underlying autistic conditions. Dev. Neurobiol. 78, 500-518. https://doi.org/10.1002/dneu.22584
- Grivennikov, S.I., Greten, F.R., and Karin, M. (2010). Immunity, inflammation, and cancer. Cell 140, 883-899. https://doi.org/10.1016/j.cell.2010.01.025
- Howe, E.A., Sinha, R., Schlauch, D., and Quackenbush, J. (2011). RNA-Seq analysis in MeV. Bioinformatics 27, 3209-3210. https://doi.org/10.1093/bioinformatics/btr490
- Jeon, J., McGinty, R.K., Muir, T.W., Kim, J.A., and Kim, J. (2018). Crosstalk among Set1 complex subunits involved in H2B ubiquitylation-dependent H3K4 methylation. Nucleic Acids Res. 46, 11129-11143. https://doi.org/10.1093/nar/gky920
- Ji, J. and Wang, X.W. (2012). Clinical implications of cancer stem cell biology in hepatocellular carcinoma. Semin. Oncol. 39, 461-472. https://doi.org/10.1053/j.seminoncol.2012.05.011
- Jones, P.A., Issa, J.P., and Baylin, S. (2016). Targeting the cancer epigenome for therapy. Nat. Rev. Genet. 17, 630-641. https://doi.org/10.1038/nrg.2016.93
- Kim, I.K., McCutcheon, J.N., Rao, G., Liu, S.V., Pommier, Y., Skrzypski, M., Zhang, Y.W., and Giaccone, G. (2019). Acquired SETD2 mutation and impaired CREB1 activation confer cisplatin resistance in metastatic non-small cell lung cancer. Oncogene 38, 180-193. https://doi.org/10.1038/s41388-018-0429-3
- Kim, K.H. and Roberts, C.W. (2016). Targeting EZH2 in cancer. Nat. Med. 22, 128-134. https://doi.org/10.1038/nm.4036
- Kudo, M., Finn, R.S., Qin, S., Han, K.H., Ikeda, K., Piscaglia, F., Baron, A., Park, J.W., Han, G., Jassem, J., et al. (2018). Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 391, 1163-1173. https://doi.org/10.1016/S0140-6736(18)30207-1
- Kwon, M., Park, K., Hyun, K., Lee, J.H., Zhou, L., Cho, Y.W., Ge, K., Skalnik, D.G., Muir, T.W., and Kim, J. (2020). H2B ubiquitylation enhances H3K4 methylation activities of human KMT2 family complexes. Nucleic Acids Res. 48, 5442-5456. https://doi.org/10.1093/nar/gkaa317
- Lee, J.H., Tate, C.M., You, J.S., and Skalnik, D.G. (2007). Identification and characterization of the human Set1B histone H3-Lys4 methyltransferase complex. J. Biol. Chem. 282, 13419-13428. https://doi.org/10.1074/jbc.M609809200
- Liedtke, M. and Cleary, M.L. (2009). Therapeutic targeting of MLL. Blood 113, 6061-6068. https://doi.org/10.1182/blood-2008-12-197061
- Llovet, J.M., Kelley, R.K., Villanueva, A., Singal, A.G., Pikarsky, E., Roayaie, S., Lencioni, R., Koike, K., Zucman-Rossi, J., and Finn, R.S. (2021). Hepatocellular carcinoma. Nat. Rev. Dis. Primers 7, 6.
- Llovet, J.M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.F., de Oliveira, A.C., Santoro, A., Raoul, J.L., Forner, A., et al. (2008). Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359, 378-390. https://doi.org/10.1056/NEJMoa0708857
- Lu, C., Klement, J.D., Yang, D., Albers, T., Lebedyeva, I.O., Waller, J.L., and Liu, K. (2020). SUV39H1 regulates human colon carcinoma apoptosis and cell cycle to promote tumor growth. Cancer Lett. 476, 87-96. https://doi.org/10.1016/j.canlet.2020.02.004
- Martin-Hijano, L. and Sainz, B., Jr. (2020). The interactions between cancer stem cells and the innate interferon signaling pathway. Front. Immunol. 11, 526.
- McCarthy, D.J., Chen, Y., and Smyth, G.K. (2012). Differential expression analysis of multifactor RNA-Seq experiments with respect to biological variation. Nucleic Acids Res. 40, 4288-4297. https://doi.org/10.1093/nar/gks042
- Miyashita, M., Oshiumi, H., Matsumoto, M., and Seya, T. (2011). DDX60, a DEXD/H box helicase, is a novel antiviral factor promoting RIG-I-like receptor-mediated signaling. Mol. Cell. Biol. 31, 3802-3819. https://doi.org/10.1128/MCB.01368-10
- Moore, S.M., Seidman, J.S., Ellegood, J., Gao, R., Savchenko, A., Troutman, T.D., Abe, Y., Stender, J., Lee, D., Wang, S., et al. (2019). Setd5 haploinsufficiency alters neuronal network connectivity and leads to autistic-like behaviors in mice. Transl. Psychiatry 9, 24.
- Oshiumi, H., Miyashita, M., Okamoto, M., Morioka, Y., Okabe, M., Matsumoto, M., and Seya, T. (2015). DDX60 is involved in RIG-I-dependent and independent antiviral responses, and its function is attenuated by virus-induced EGFR activation. Cell Rep. 11, 1193-1207. https://doi.org/10.1016/j.celrep.2015.04.047
- Osipovich, A.B., Gangula, R., Vianna, P.G., and Magnuson, M.A. (2016). Setd5 is essential for mammalian development and the co-transcriptional regulation of histone acetylation. Development 143, 4595-4607.
- Piao, L., Li, H., Feng, Y., Yang, Z., Kim, S., and Xuan, Y. (2020). SET domain-containing 5 is a potential prognostic biomarker that promotes esophageal squamous cell carcinoma stemness. Exp. Cell Res. 389 , 111861.
- Pietras, E.M., Lakshminarasimhan, R., Techner, J.M., Fong, S., Flach, J., Binnewies, M., and Passegue, E. (2014). Re-entry into quiescence protects hematopoietic stem cells from the killing effect of chronic exposure to type I interferons. J. Exp. Med. 211, 245-262. https://doi.org/10.1084/jem.20131043
- Qiu, Z., Li, H., Zhang, Z., Zhu, Z., He, S., Wang, X., Wang, P., Qin, J., Zhuang, L., Wang, W., et al. (2019). A pharmacogenomic landscape in human liver cancers. Cancer Cell 36, 179-193.e11. https://doi.org/10.1016/j.ccell.2019.07.001
- Reikine, S., Nguyen, J.B., and Modis, Y. (2014). Pattern recognition and signaling mechanisms of RIG-I and MDA5. Front. Immunol. 5, 342.
- Saung, M.T., Pelosof, L., Casak, S., Donoghue, M., Lemery, S., Yuan, M., Rodriguez, L., Schotland, P., Chuk, M., Davis, G., et al. (2021). FDA approval summary: nivolumab plus ipilimumab for the treatment of patients with hepatocellular carcinoma previously treated with sorafenib. Oncologist 26, 797-806. https://doi.org/10.1002/onco.13819
- Sessa, A., Fagnocchi, L., Mastrototaro, G., Massimino, L., Zaghi, M., Indrigo, M., Cattaneo, S., Martini, D., Gabellini, C., Pucci, C., et al. (2019). SETD5 regulates chromatin methylation state and preserves global transcriptional fidelity during brain development and neuronal wiring. Neuron 104, 271-289.e13. https://doi.org/10.1016/j.neuron.2019.07.013
- Shechter, D., Dormann, H.L., Allis, C.D., and Hake, S.B. (2007). Extraction, purification and analysis of histones. Nat. Protoc. 2, 1445-1457. https://doi.org/10.1038/nprot.2007.202
- Shen, H. and Laird, P.W. (2013). Interplay between the cancer genome and epigenome. Cell 153, 38-55. https://doi.org/10.1016/j.cell.2013.03.008
- Siegel, R.L., Miller, K.D., and Jemal, A. (2018). Cancer statistics, 2018. CA Cancer J. Clin. 68, 7-30. https://doi.org/10.3322/caac.21442
- Sowalsky, A.G., Xia, Z., Wang, L., Zhao, H., Chen, S., Bubley, G.J., Balk, S.P., and Li, W. (2015). Whole transcriptome sequencing reveals extensive unspliced mRNA in metastatic castration-resistant prostate cancer. Mol. Cancer Res. 13, 98-106. https://doi.org/10.1158/1541-7786.MCR-14-0273
- Tang, Z., Kang, B., Li, C., Chen, T., and Zhang, Z. (2019). GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res. 47(W1), W556-W560. https://doi.org/10.1093/nar/gkz430
- Uhlen, M., Zhang, C., Lee, S., Sjostedt, E., Fagerberg, L., Bidkhori, G., Benfeitas, R., Arif, M., Liu, Z., Edfors, F., et al. (2017). A pathology atlas of the human cancer transcriptome. Science 357, eaan2507.
- Vougiouklakis, T., Bernard, B.J., Nigam, N., Burkitt, K., Nakamura, Y., and Saloura, V. (2020). Clinicopathologic significance of protein lysine methyltransferases in cancer. Clin. Epigenetics 12, 146.
- Wang, Z., Hausmann, S., Lyu, R., Li, T.M., Lofgren, S.M., Flores, N.M., Fuentes, M.E., Caporicci, M., Yang, Z., Meiners, M.J., et al. (2020). SETD5-coordinated chromatin reprogramming regulates adaptive resistance to targeted pancreatic cancer therapy. Cancer Cell 37, 834-849.e13. https://doi.org/10.1016/j.ccell.2020.04.014
- Worns, M.A. and Galle, P.R. (2010). Future perspectives in hepatocellular carcinoma. Dig. Liver Dis. 42 Suppl 3, S302-S309. https://doi.org/10.1016/S1590-8658(10)60521-X
- Yang, Z., Zhang, C., Che, N., Feng, Y., Li, C., and Xuan, Y. (2021). Su(var)3-9, Enhancer of zeste, and Trithorax domain-containing 5 facilitates tumor growth and pulmonary metastasis through up-regulation of AKT1 signaling in breast cancer. Am. J. Pathol. 191, 180-193. https://doi.org/10.1016/j.ajpath.2020.10.005
- Yu, H., Sun, J., Zhao, C., Wang, H., Liu, Y., Xiong, J., Chang, J., Wang, M., Wang, W., Ye, D., et al. (2019). SET domain containing protein 5 (SETD5) enhances tumor cell invasion and is associated with a poor prognosis in non-small cell lung cancer patients. BMC Cancer 19, 736.